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Abstract
Adipose tissue not only possesses an important role in the storage of excess 
nutrients but also acts as a critical immune and endocrine organ. Researchers and 
clinicians now consider adipose tissue to be an active endocrine organ that secretes 
various humoral factors called “adipokines,” which imparts important systemic 
metabolic effects, from food intake to glucose tolerance. Along with its production 
of specialized adipokines, adipose tissue also secretes proinflammatory cytokines 
that likely contributes to the low-level systemic inflammation that has become a 
hallmark of various metabolic syndrome-associated chronic pathologies, such as 
obesity and cancer cachexia. These systemic effects may be mediated by commu-
nication networks arising from the multitude of resident adipose cells, including 
adipocytes, endothelial cells, neuronal cells, stem cells and other precursors, and a 
wide variety of immune cell populations that recent studies have demonstrated play 
a crucial role in the development of adipose inflammation and systemic metabolic 
abnormalities. In this chapter, we detail various molecular pathways linking excess 
adipose lipid storage to chronic inflammation and review the current knowledge as 
to what triggers obesity- and cachexia-associated inflammation in adipose tissue. 
Finally, we describe how the cross talk between adipose tissue inflammation and 
the non-adipocyte resident cells present in tissue is involved in this metabolic 
disruption.
Keywords: adipokines, remodeling, cross talk, cachexia, obesity
1. Introduction
In recent years, adipose tissue has rapidly emerged as a critical player in main-
taining an organism’s metabolic homeostasis through its canonical role in storing 
excess energy, as well as its emerging role in facilitating communication modalities 
critical to maintaining systemic metabolism. These diverse abilities possessed by 
adipose tissue directly results from its heterogeneous composition which allows for 
the integration and propagation of signals that influence whole-body homeostasis. 
To be effective in reacting to alterations within the organism, the adipose tissue 
must be dynamic and remodel itself in order to preserve the health of the organism. 
While remodeling allows for the maintenance of homeostasis, this mechanism may 
become compromised in certain metabolic diseases, such as cancer cachexia and 
obesity. Here, the influence of adipose heterogeneity on tissue remodeling in the 
context of cancer cachexia and obesity will be further discussed.
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2. The adipose tissue
2.1 Adipose heterogeneity
Adipose tissue, or fat tissue, is classified in morphofunctional term into two dis-
tinct groups; (1) white adipose tissue (WAT), composed predominantly of unilocu-
lar adipocytes, with low mitochondrial density and low oxidative capacity, and (2) 
brown adipose tissue (BAT), predominantly composed of multilocular adipocytes, 
high mitochondrial density and oxidative capacity for the uptake and oxidation of 
fatty acids and glucose related to the maintenance and regulation of body tempera-
ture [1]. Other differences between the two types of adipose tissues are the depot 
localization, profile of secreted molecules, cell population, vascularization and also 
innervation [2–4]. While both of these adipose tissue groups contribute a signifi-
cant role in maintaining systemic homeostasis, WAT is the primary site of metabolic 
dysregulation in many metabolic diseases [5, 6].
WAT is divided into two large depots, subcutaneous adipose tissue (scWAT) 
and visceral adipose tissue (vWAT). scWAT is present in the innermost layers of 
the skin (hypodermis), while vWAT is located in the internal organs [7]. In addi-
tion, it is well described, both in experimental and clinical research, that adipose 
tissue is a heterogeneous tissue, that presents different gene and protein expres-
sion profiles, as well as cellular composition depending on the location of the 
tissue [8, 9]. scWAT represents approximately 80% of the total fat mass in healthy 
individuals, while vWAT accounts for between 10 and 20% of the total body fat 
of lean men, and between 5 and 10% of total fat in women [10]. vWAT has been 
shown to be more metabolically responsive, and its accumulation has a higher 
correlation with obesity-related mortality [11].
The morphological composition of adipose tissue plays an important role in the 
homeostatic maintenance and tissue development. Adipose tissue is a special type 
of connective tissue composed of different cell types composed of approximately 
50–70% adipocytes and 30–50% of stromal vascular fraction (SVF) cells, where the 
mesenchymal precursor cells, pre-adipocytes, fibroblasts, leukocytes, blood vessels, 
lymph nodes and nerves are present (Figure 1) [12–14]. Numerous studies have 
shown the cellular heterogeneity of adipose tissue is a critical component in the 
Figure 1. 
Adipose tissue cellularity. The vast majority of the adipose tissue mass is composed of adipocytes 
(approximately 60%). There are many other cell types present in the adipose tissue. This specific portion of 
non-adipocytes is called the stromal vascular fraction (SVF) that is approximately 30% of the total cells in the 
tissue. In this portion are present mesenchymal precursor cells, pre-adipocytes, macrophages, others immune 
cells and endothelial cells.
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tissue’s ability to act as a hub of metabolic equilibrium [8, 15, 16]. Discovering and 
understanding the role of each cell present in adipose tissue leads to a greater chance 
in the development of possible therapeutics targeting metabolic disorders, which 
places a greater emphasis on studies of adipose cellularity.
2.2 Adipose tissue as an endocrine organ
This endocrine role of adipose tissue is best characterized by leptin [17, 18]. In 
1994, with the discovery of leptin, the perception of WAT evolved from simply an 
energy storage compartment, mechanical protector and thermal insulation, but 
also an endocrine organ due the identification of a multitude of adipocyte-secreted 
factors that can act on distal tissues to regulate systemic functions, such as immu-
nological and inflammatory responses, regulation of appetite, vascular events, 
control of reproductive functions, and insulin sensitivity [17, 19]. Total deficiency 
or insensitivity to leptin causes hyperphagia, morbid obesity, diabetes, a variety of 
neuroendocrine abnormalities, and autonomic and immunologic dysfunction [20].
Studies show that adipose tissue-derived hormones, fatty acids, lipids and 
signaling molecules, act by exerting endocrine, autocrine and paracrine effects. 
These factors are part of the large family of proteins and small molecules released 
by adipose tissue, which collectively are called adipokines [17, 21]. This tremendous 
diversity of signaling molecules enables the adipose tissue to engage in a wide 
array of signaling modalities that allows for systemic regulation of an organism’s 
physiology (Figure 2). In instances of whole-body metabolic dysregulation, such 
as cancer cachexia and obesity, alterations to adipose tissue composition may have 
drastic effects on adipokine production. These effects are of critical importance in 
understanding the manifestation of metabolic syndromes. One example of such 
a dysregulation in adipokine profile is the release of pro- and anti- inflammatory 
adipokines during pathophysiological processes. This adipokine dysregulation 
Figure 2. 
Adipose tissue as endocrine organ. Endocrine factors released by white fat may signal to distant issues, including 
the brain, muscle, liver, heart and pancreas that regulate glucose and fatty acid metabolism in peripheral 
tissues, energy homeostasis, inflammatory response, and blood pressure, among others. Imbalanced secretion of 
some of these adipokines is associated with metabolic disorders. These factors released by white adipose tissue 
may target itself in an autocrine and paracrine manner, and also activate distant tissues in an endocrine 
manner (e.g., brown adipose tissue). Abbreviations see appendices and nomenclature section.
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contributes significantly to the disruption of adipose tissue homeostasis in these 
diseases. Excessive secretion of potentially harmful adipokines (e.g., PAI-1, TNF-α 
and IL6) and hyposecretion of potentially beneficial adipokines, (e.g., adipo-
nectin), may play an important role in the major mechanisms involved in during 
metabolic diseases. Thus, understanding the mechanism of various metabolic 
diseases calls for a deep understanding of the relationship between adipose tissue 
cellular composition and function.
2.3 Adipose tissue remodeling
Adipose tissue can respond rapidly and dynamically depending on the situation 
involved, thus fulfilling its major role in preserving whole-body energy homeostasis 
[22, 23]. Adipose tissue remodeling is a continuous process that is involved in some 
metabolic syndromes, such as reduction of vascular remodeling [24], overproduc-
tion of extracellular matrix [25], altered immune cell populations, and inflam-
matory responses are classic tissue response to such metabolic imbalances [26]. 
However, not all remodeling of adipose tissue is necessarily associated with patho-
logical changes. A classic example is a concept of “metabolically healthy obesity” 
[27, 28], suggesting that some individuals may preserve systemic insulin sensitivity 
based on the “healthy” expansion of adipose tissue, avoiding the pathological con-
sequences associated with obesity. Among the various consequences that can arise 
from adipose tissue remodeling is a state of local inflammation. This inflammatory 
state has been implicated in the progression of systemic dysregulation of metabo-
lism in instances of “metabolically unhealthy obesity” [29]. Thus, comprehending 
the role of inflammation in the remodeling process of the adipose tissue is essential 
in understanding the main pathological alterations of this tissue.
2.3.1 An overview of adipose tissue inflammation
The adipose tissue plays host to a variety of immune cell populations that are 
intimately involved in the remodeling state of the tissue. Adipose tissue resident 
cells can secrete several proinflammatory cytokines that can orchestrate the inflam-
matory state of the tissue by influencing these immune cell populations within the 
tissue itself [21]. These inflammatory mediators have several metabolic and endo-
crine functions (immunity, metabolism, energy balance, among others), which is 
intimal related to the inflammatory process and immune system response [30, 31].
Inflammation in adipose tissue rose to prominence in the mid-1990s, shortly 
after obesity was recognized as an inflammatory disease in a study conducted 
with rats, which demonstrated greater expression of the gene encoding the pro-
inflammatory cytokine TNF-α in adipose tissue, as well as a reduction in insulin 
sensitivity after exposure to a weight-gain diet [32]. In recent decades, data from 
human studies and transgenic animal models have strongly suggested correlative 
but also causative associations between the activation of proinflammatory pathways 
and insulin resistance [33, 34]. Particularly, chronic inflammation in adipose tissue 
appears to play an important role in the development of insulin resistance related to 
obesity and others metabolic diseases [33, 35]. The following potential mechanisms 
of adipose tissue inflammation and how this state is involved during the pathologi-
cal process of cancer-associated cachexia and obesity are discussed.
2.3.2 Adipose tissue inflammation during cancer cachexia
Cancer cachexia syndrome is characterized by systemic inflammation, body 
weight loss, adipose tissue remodeling, and skeletal muscle wasting that cannot be 
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fully reversed by conventional nutritional support and leads to progressive func-
tional impairment [36]. Interesting, that adipose tissue of cachectic cancer patients 
is a possible relevant systemic source of inflammatory molecules during the devel-
opment of the disease [37]. Moreover, it is now well described in both experimental 
and clinical research that these changes are dependent on the location of adipose 
tissue (e.g., visceral versus subcutaneous), which is involved in differential depot 
response to the disease [8, 38]. WAT also secretes and responds to pro-inflammatory 
mediators, as it also expresses several receptors for these secreted cytokines, 
chemokines, complement and growth factors [39]. These mediators act locally in an 
autocrine and/or paracrine manner, as well as distally in an endocrine fashion that 
can regulate appetite, modulate energy expenditure and affect a range of physi-
ological processes, including insulin sensitivity and inflammatory responses [40].
Some interesting studies proposed that an imbalance between catabolic and 
anabolic processes in WAT is associated with the progression of cachexia. The 
proinflammatory cytokines interleukin 1-beta (IL-1β), interferon gamma (IFN-γ), 
interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) appear respon-
sible for the activation of WAT catabolism in experimental models [37, 41–44]. 
Additionally, studies have demonstrated a predominance of an inflammatory 
profile in the terminal phase of the cachexia syndrome, notably within vWAT [45]. 
The presence of an important macrophage infiltration in this depot in rats with 
cancer cachexia was verified, which has been shown to contribute to the secretion 
of inflammatory factors [45]. More recently, in the same model of cancer cachexia, 
Batista et al. [41] showed an increase of macrophages around the adipocytes that 
were are polarized to a proinflammatory state in the vWAT simultaneously with the 
activation of the inflammasome pathway in this specific depot [43]. This event was 
immediately preceded by an increase in neutrophil density within the depot, which 
usually occurs in the intermediate phases of the syndrome. Therefore, depending 
on the inflammatory phase, distinct cell types can be observed. In fact, in several 
inflammatory processes, chronic inflammation is characterized by the presence 
of mononuclear cells that is usually preceded by tissue infiltration of neutrophils, 
which are cells that characterize acute inflammation [46].
In addition to animal models of cachexia, a study has recently demonstrated 
the presence of an exacerbated inflammatory profile in the WAT of humans with 
cancer cachexia [38]. In particular, an increase in CD68 positive cells, indicative of 
macrophages, and the clustering of the classic “crown-like structure” around the 
adipocyte were described. This morphological characteristic, although well-detailed 
in an obesity model, was described for the first time in cachexia. In the same study, 
an increase in CD3, a lymphocyte marker, and total collagen-positive cells in the 
WAT of these patients with cachexia was also detected. Taken together, the data 
indicate the presence of morphological alterations that suggest WAT remodeling in 
the presence of cachexia in humans [38].
However, despite the relevance of local inflammation, notably in WAT, the 
mechanisms that result in this process still require further detailing. Another 
important aspect is the characterization and understanding of the inflammatory 
process in this condition and its possible relation with the metabolic disorders, in 
order to answer if this process is secondary or the “trigger” for the development 
of the syndrome. Understanding the basic mechanisms of cancer cachexia that 
orchestrate WAT remodeling is relevant for the development of new pharmacologi-
cal and nutritional therapies for anti-cachectic purposes. In this context, further 
demonstrating an intimate correlation between inflammation and the prognosis of 
cancer-associated cachexia, it was demonstrated that a genetic and pharmacological 
(atorvastatin) model of Toll-like receptor 4 (TLR4) inhibition, one of the primary 
inflammatory mediators, was able to attenuate classic symptoms of cachexia in an 
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animal model [47]. This suggests that an important inflammatory pathway may be 
considered a promising target for therapeutic actions. It also further elucidates the 
mechanism by which cancer cachexia is manifested [47].
2.3.3 Adipose tissue inflammation during obesity
The incidence of overweight and obesity has increased substantially in the last 
decades worldwide is considered a worldwide epidemic, reducing the quality of life 
due to an increase in the physical and metabolic disability of individuals [48]. This 
occurs, at least partially, because of the obesity-induced insulin resistance and the 
fact that adipose tissue is not only an energy reservoir but also a secretory endocrine 
organ of cytokines, hormones, and proteins that affect the functionality of cells and 
tissues all over the body [49].
Recent studies have established association between obesity and systemic 
chronic low-grade inflammation [30, 50]. This association is characterized by, 
among other things, higher levels of circulating proinflammatory cytokines and 
fatty acids that can contribute to the development of the metabolic dysfunctions 
involved in the pathogenesis of its comorbidities [51].
It is well known that during this inflammation state in the adipose tissue, the tissue 
starts an intense remodeling in the adipose cell types present in the tissue. A major type 
of cell that plays an important role in the adipose tissue is the macrophages. Adipose 
tissue macrophage can be characterized in two different classes based on the expres-
sion of particular markers [52]. M1 macrophages or classically activated macrophages 
are characterized by nitric oxide synthase (iNOS) and CD11c surface expression, and 
expression of pro-inflammatory cytokines [53]. On the other hand, M2 macrophages or 
alternatively activated macrophages, are characterized by Arginase 1 (Arg1) and CD206 
surface expression, and secrete anti-inflammatory cytokines predominates [53].
Figure 3. 
Features in adipose tissue inflammation. Healthy adipose tissue displays high insulin sensitivity and is 
characterized by an anti-inflammatory state marked by elevated levels of adipocyte progenitor cells and 
M2 macrophages, sufficient vasculature to support tissue expansion and adipocyte hyperplasia. In an obese 
state, the adipose tissue contains hypertrophic adipocytes and a state of chronic inflammation exists within 
the tissue. A large increase in the populations of M1 proinflammatory macrophages, along with several 
other inflammatory leukocytes, begins to infiltrate the inflamed tissue. In addition, it is possible to observe a 
reduction in the vascularization of this unhealthy fat, resulting in a hypoxic state. Chronic inflammation results 
in the development of fibrotic structures in the form of increased extracellular components, such as collagen. 
Such events contribute to the development of insulin resistance.
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A proposed model was defined as “phenotypic switching” that means an 
enhanced adipose tissue macrophage infiltration aggravates the environment of 
obesity-related inflammation [54]. This model emphasized that obesity starts to 
induced a polarization in these macrophage cells present in the tissue, that now the 
ratio M1/M2 macrophage are dysregulated and the M1 macrophage population are 
predominate in the adipose tissue [54]. Interesting that some studies showed that 
M1 macrophage population demonstrates a positive correlation with insulin resis-
tance and an increase in proinflammatory responses [55]. Therefore, these studies 
suggest a sophisticated balance in relation to the diversity of macrophages popula-
tion is necessary to sustain the adipose tissue homeostasis.
In addition to this deregulation in macrophages infiltration, other major changes 
also appear in the inflamed adipose tissue during obesity. Modifications in the 
composition of the extracellular matrix, decreased in the vascularization and altera-
tions in the composition of immune cells in tissue are classic features of this adipose 
tissue remodeling [24, 26, 56] (Figure 3).
3. Concluding remarks
In summary, certain metabolic disease states, such as cancer cachexia and 
obesity, may alter the heterogeneous composition of adipose tissue, resulting in 
a remodeled tissue that is unable to properly respond to the systemic needs of the 
organism. We know that the adipose heterogeneity cells present in the tissue are the 
extremely importance in to regulate the homeostasis, and in the time that adipose 
tissue is affected to some metabolic syndrome this cross talk is deregulated and the 
homeostasis is compromised. After the adipose tissue is committed by a metabolic 
syndrome, the tissue starts to react in several ways. Several studies using cachexia 
and obesity experimental models have consistently indicated that a classic response 
to this imbalance, showed an intense adipose tissue remodeling in which the 
tissue begins to present numerous alterations in the morphology and also genetic 
alterations where its function ends up being extremely compromised. Finally, a 
deeper understanding of the initial stimulus and also who are the main types of 
cells involved in adipose tissue remodeling is essential for understanding the basic 
mechanisms in which adipose tissue performs. Once we have managed to obtain the 
answers to these important issues, we will be able to advance and have the chance to 
achieve some possible therapeutic target to these severe metabolic diseases.
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ECM extracellular matrix
GDF15 growth differentiation factor 15





NEGR1 neuronal growth regulator 1
NGF nerve growth factor
NRG4 neuregulin 4
PAI-1 plasminogen activator inhibitor-1
scWAT subcutaneous adipose tissue
SVF stromal vascular fraction
TGF-β transforming growth factor β
TLR4 Toll-like receptor 4
TNFα tumor necrosis factor α
UCP1 uncoupling protein 1
vWAT visceral adipose tissue
VEGF vascular endothelial growth factor
WAT white adipose tissue
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